ArticleCureus2025
Clear Cell Sarcoma of the Knee: A Case Report of Diagnostic Challenges, Rapid Metastatic Spread, and Treatment Dilemmas.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell sarcoma (CCS) is a rare, aggressive soft tissue sarcoma with a strong predilection for the extremities. It is often misdiagnosed as melanoma. Despite surgical resection, CCS carries a high risk of early metastasis, most commonly to the lungs, bones, and lymph nodes, with limited effective systemic therapies available. We present the case of a 48-year-old man with CCS of the knee, initially presenting as a localized disease but rapidly progressing to widespread metastasis within three months. The patient underwent radical resection with knee arthroplasty and adjuvant radiotherapy, followed by systemic therapy with cabozantinib, ipilimumab, and nivolumab. Despite aggressive treatment, the disease progressed, leading to recurrent pleural effusions, respiratory failure, and, ultimately, the patient's demise within 10 months of diagnosis. This case underscores the highly aggressive nature of CCS and the challenges associated with its management. The rapid metastatic spread despite multimodal therapy highlights the need for improved early detection strategies and more effective systemic treatments, including novel targeted therapies and immunotherapy combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.